Journal article
Glucocorticoids and Cancer
Advances in experimental medicine and biology, Vol.872, pp.315-333
2015
DOI: 10.1007/978-1-4939-2895-8_14
PMCID: PMC5546099
PMID: 26216001
Abstract
Unlike other steroid hormone receptors, the glucocorticoid receptor (GR) is not considered an oncogene. In breast cancer, the estrogen receptor (ER) drives cell growth, proliferation, and metastasis, and the androgen receptor (AR) plays a similar role in prostate cancer. Accordingly, treatment of these diseases has focused on blocking steroid hormone receptor function. In contrast, glucocorticoids (GCs) work through GR to arrest growth and induce apoptosis in lymphoid tissue. Glucocorticoids are amazingly effective in this role, and have been deployed as the cornerstone of lymphoid cancer treatment for decades. Unfortunately, not all patients respond to GCs and dosage is restricted by immediate and long term side effects. In this chapter we review the treatment protocols that employ glucocorticoids as a curative agent, elaborate on what is known about their mechanism of action in these cancers, and also summarize the palliative uses of glucocorticoids for other cancers.
Details
- Title: Subtitle
- Glucocorticoids and Cancer
- Creators
- Miles A Pufall - Department of Biochemistry, Carver College of Medicine, Holden Comprehensive Cancer Center, 51 Newton Road, Bowen Science Building, Room 4-430, Iowa City, IA, 52242, USA, miles-pufall@uiowa.edu
- Resource Type
- Journal article
- Publication Details
- Advances in experimental medicine and biology, Vol.872, pp.315-333
- DOI
- 10.1007/978-1-4939-2895-8_14
- PMID
- 26216001
- PMCID
- PMC5546099
- NLM abbreviation
- Adv Exp Med Biol
- eISBN
- 1493928953; 9781493928958
- ISSN
- 0065-2598
- eISSN
- 2214-8019
- Publisher
- United States
- Grant note
- R00 CA149088 / NCI NIH HHS K99 CA149088 / NCI NIH HHS
- Language
- English
- Date published
- 2015
- Academic Unit
- Biochemistry and Molecular Biology
- Record Identifier
- 9984025300302771
Metrics
25 Record Views